Boston Scientific Co. (NYSE:BSX) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 741,769 shares of the medical equipment provider's stock after buying an additional 122,979 shares during the period. Russell Investments Group Ltd. owned 0.05% of Boston Scientific worth $42,743,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. FMR LLC grew its holdings in shares of Boston Scientific by 6.8% in the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider's stock valued at $6,648,595,000 after buying an additional 8,045,263 shares during the period. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.2% during the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider's stock worth $6,534,969,000 after purchasing an additional 1,525,432 shares during the period. Wellington Management Group LLP grew its position in shares of Boston Scientific by 5.9% in the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider's stock valued at $2,221,641,000 after purchasing an additional 2,336,348 shares during the period. Morgan Stanley increased its stake in Boston Scientific by 2.3% during the 3rd quarter. Morgan Stanley now owns 21,200,339 shares of the medical equipment provider's stock worth $1,119,378,000 after purchasing an additional 481,891 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Boston Scientific by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 17,207,345 shares of the medical equipment provider's stock valued at $908,548,000 after buying an additional 51,293 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. Evercore ISI lifted their target price on Boston Scientific from $72.00 to $78.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Raymond James upped their price target on Boston Scientific from $73.00 to $85.00 and gave the stock a "strong-buy" rating in a research report on Thursday, April 25th. Wells Fargo & Company increased their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an "overweight" rating in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Boston Scientific from $63.00 to $73.00 and gave the company a "hold" rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $75.09.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.64 on Tuesday, hitting $71.86. The company's stock had a trading volume of 8,713,114 shares, compared to its average volume of 6,648,357. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $74.39. The company has a market capitalization of $105.43 billion, a PE ratio of 60.91, a PEG ratio of 2.52 and a beta of 0.78. The stock's 50 day moving average is $67.96 and its 200-day moving average is $60.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.59 billion. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. During the same period in the previous year, the company posted $0.45 earnings per share. Equities research analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares of the company's stock, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at $17,883,756.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,797 shares of company stock worth $4,138,090. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.